Sunday, 22 November 2026 SEC EDGAR filings, as they land
ALFAFINDER USA News Straight from the SEC filing
SEC Filings
Capital Raise

SELLAS Life Sciences Prices $172.5 Million Public Offering to Fund Clinical Pipeline

SELLAS Life Sciences has priced a common stock offering at $13.00 per share, significantly bolstered by the full exercise of the underwriters' overallotment option. The $172.5 million in gross proceeds will support the clinical progression of its lead oncology candidates, GPS and SLS009.

Pink ribbon, breast cancer awareness month, breast cancer, prevention. Stock photo illustrating SELLAS Life Sciences' capital raise story.
SELLAS Life Sciences Group, Inc. · Healthcare · Photo: marijana1 / Pixabay
Key numbers
Deal value$172M
Share of market cap5.7%

Key highlights

  • Public offering of 11,538,462 shares priced at $13.00 per share
  • Underwriters fully exercised their option for an additional 1,730,769 shares
  • Total gross proceeds reached approximately $172.5 million
  • Estimated net proceeds of $161.8 million after fees and expenses
  • Lead book-running managers included J.P. Morgan, TD Cowen, and Mizuho

What Is the Capital Raise?

SELLAS Life Sciences Group, Inc. has structured an underwritten public offering involving the sale of 11,538,462 shares of common stock. The offering was priced at $13.00 per share, a figure notably influenced by current market conditions for clinical-stage biotechnology firms. To accommodate excess demand, the company granted underwriters a 30-day option to purchase up to 1,730,769 additional shares, which was exercised in full at the time of pricing. This expansion brought total gross proceeds to approximately $172.5 million. The transaction is expected to close on November 20, 2026, pending the satisfaction of customary closing conditions.

Use of Proceeds

  • Funding the continued clinical development of lead product candidate GPS
  • Advancing the SLS009 small molecule CDK9 inhibitor program
  • Supporting general corporate purposes and working capital requirements
  • Addressing costs associated with ongoing late-stage clinical trials

Business Overview

Based in New York, SELLAS is a late-stage clinical biopharmaceutical company targeting a diverse range of cancer indications. Its primary asset, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein. GPS is being evaluated as both a monotherapy and in combination with other agents to treat hematologic malignancies and solid tumors. Additionally, the company is developing SLS009 for patients with acute myeloid leukemia who possess unfavorable prognostic factors. These programs represent the core of the company's efforts to address high unmet needs in oncology through novel therapeutic mechanisms.

Financial Context

Prior to this capital raise, SELLAS maintained a market capitalization of approximately $3.03 billion. The stock experienced significant volatility, reflected in a 17.21% decline on the day of the pricing announcement, which is typical for dilutive equity offerings in the biotech sector. Despite this daily dip, the ticker has demonstrated robust momentum with an 85.06% increase over the preceding week. The relative strength index stands at 60.2, indicating the stock remains within neutral technical territory. This capital influx provides a necessary liquidity cushion for intensive research expenditures and ongoing clinical milestones.

SELLAS Life Sciences Group, Inc. share price · last month
Line chart of SELLAS Life Sciences Group, Inc.'s share price over the last month, from $12.14 on 21 Oct → $13.66 on 20 Nov; our story on 20 Nov at $14.86.

Down 8.1% since our story on 20 Nov: $14.86 when we broke it → $13.66 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
21 Oct$12.14
22 Oct$11.35
23 Oct$11.54
26 Oct$11.34
27 Oct$12.17
28 Oct$10.38
29 Oct$10.16
30 Oct$9.68
2 Nov$8.55
3 Nov$8.87
4 Nov$9.14
5 Nov$7.88
6 Nov$8.42
9 Nov$8.58
10 Nov$8.37
11 Nov$8.42
12 Nov$8.03
13 Nov$7.86
16 Nov$7.47
17 Nov$19.15
18 Nov$17.95
19 Nov$14.86
20 Nov$13.66
SELLAS Life Sciences Group, Inc. · financial snapshot
Share price$14.86
Market cap$3.0B
1-month price change+24.04%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by SELLAS Life Sciences Group, Inc. announcing the pricing of an underwritten public offering.

Read the filing ↗
All SELLAS Life Sciences Group, Inc. filings and newsView all →

Track SELLAS Life Sciences Group, Inc. live

Get the next SELLAS Life Sciences Group, Inc. SEC filing seconds after it lands.

More from SELLAS Life Sciences Group, Inc.

All →

More in Capital Raise

All →

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.